Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
Clinical study BCD‐201‐1 is a double‐blind randomized study of the pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity of BCD‐201 versus Keytruda following intravenous administration to subjects with advanced unresectable, metastatic, or recurrent melanoma and NSCLC. The study aimed to establish the equivalence of PK and similarity of the safety, immunogenicity, and PD profiles of BCD‐201 and Keytruda.
Epistemonikos ID: 38baa6105e7a2b507ff68423852d7f0351123af3
First added on: Feb 19, 2024